Tenax Therapeutics receives U.S. patent for oral levosimendan (TNX-103) in PH-HFpEF, expiring 2040

TENAX THERAPEUTICS, INC.

USPTO granted Patent No. 11,701,355 for oral levosimendan (TNX-103) to treat PH-HFpEF, with exclusivity through December 2040.
No FDA-approved treatments exist for PH-HFpEF, which affects over 1.6 million North Americans, projected to exceed 2 million by 2030.
Phase 2 HELP study showed statistically significant improvement in 6-minute walk distance for levosimendan.
Tenax intends to initiate a Phase 3 trial of TNX-103 in 2023, planning to demonstrate efficacy in this underserved patient population.
Patent builds on existing IP for IV and subcutaneous levosimendan formulations for PH-HFpEF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.